A G6PD test is a blood draw to check levels of glucose-6-phosphate dehydrogenase (G6PD). G6PD is a protein that supports red blood cell function. If you have low G6PD, you may develop hemolytic anemia, which occurs when your body destroys red blood cells faster than it makes them. You may need a G6PD test if you have symptoms of hemolytic anemia.

1.The SD Biosensor STANDARD G6PD test is designed to measure the quantitative concentration of total hemoglobin (g/dL) and G6PD enzymatic activity (U/g Hb) in fresh human whole blood based on reflectometry assays. 2.Qualitative tests give a deficient/normal read out for G6PD deficiency.

8.6 to 18.6 units/gram of hemoglobin

The G6PD quantitative test measures the level of glucose-6-phosphate dehydrogenase (G6PD) enzyme activity in the blood. Here's how to interpret the results: Normal Range: The normal range for G6PD enzyme activity varies depending on the laboratory and the method used for testing. Enzyme activity levels are typically reported in international units per gram of hemoglobin (IU/g Hb) or as a percentage of normal activity. Normal Activity: Normal or adequate G6PD enzyme activity indicates that the individual has sufficient levels of the enzyme to protect red blood cells from oxidative damage. Interpretation: Normal G6PD enzyme activity suggests that the individual is not at risk of hemolysis (destruction of red blood cells) due to G6PD deficiency. Individuals with normal enzyme activity levels do not require specific precautions related to G6PD deficiency. Low Activity: Reduced G6PD enzyme activity indicates G6PD deficiency, a genetic condition characterized by insufficient levels of the G6PD enzyme. Interpretation: Low G6PD enzyme activity increases the risk of hemolysis in response to certain triggers, such as certain medications, infections, or ingestion of certain foods. The severity of symptoms and the risk of hemolysis depend on the degree of enzyme deficiency and the specific trigger. Individuals with G6PD deficiency may experience episodes of hemolytic anemia, jaundice, dark urine, and symptoms of anemia during hemolytic crises. Clinical Correlation: Interpretation of G6PD quantitative test results should be done in conjunction with clinical findings, medical history, and other diagnostic tests. Knowledge of G6PD enzyme activity levels can help guide the management and treatment of individuals with suspected or confirmed G6PD deficiency. Additional testing, such as G6PD genotyping, may be necessary to confirm the diagnosis and identify the specific G6PD variant. Precautions: Individuals with G6PD deficiency should avoid known triggers of hemolysis, including certain medications (e.g., antimalarials, sulfa drugs, nitrofurantoin), fava beans, and certain infections. Healthcare providers should be aware of the patient's G6PD status when prescribing medications and consider alternative therapies if necessary. Genetic Counseling: Genetic counseling may be recommended for individuals with G6PD deficiency, especially those planning to start certain medications or undergo procedures that may trigger hemolysis. Counseling can help individuals understand the inheritance pattern of G6PD deficiency and make informed decisions about their health and treatment options. Interpretation of G6PD quantitative test results should be performed by healthcare providers familiar with the diagnosis and management of G6PD deficiency. It's important to consider the clinical context, symptoms, and potential triggers of hemolysis when interpreting test results and determining appropriate management strategies.

Blood